This approach has also been investigated in different clinical trials (Table 4), resulting in the recent Food and Drug Administration (FDA) approval of PD-1 inhibitor pembrolizumab in combination with the anti-VEGFR kinase inhibitor axitinib for the frontline treatment of patients with advanced renal cell carcinoma [32]. Here, PDCD1 is linked to hereditary clear cell renal cell carcinoma.